Equities

Neogenomics Inc

Neogenomics Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)15.77
  • Today's Change-0.05 / -0.32%
  • Shares traded1.13m
  • 1 Year change-0.38%
  • Beta1.1968
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy4
Outperform6
Hold4
Sell0
Strong Sell0

Share price forecast in USD

The 12 analysts offering 12 month price targets for NeoGenomics, Inc. have a median target of 19.50, with a high estimate of 30.00 and a low estimate of 16.00. The median estimate represents a 23.65% increase from the last price of 15.77.
High90.2%30.00
Med23.7%19.50
Low1.5%16.00

Earnings history & estimates in USD

On Nov 05, 2024, NeoGenomics, Inc. reported 3rd quarter 2024 earnings of 0.05 per share. This result was in line with the consensus of the 14 analysts following the company and outperformed last year's 3rd quarter results by 0.05.
The next earnings announcement is expected on Feb 18, 2025.
Average growth rate+66.67%
NeoGenomics, Inc. reported annual 2023 losses of -0.12 per share on Feb 20, 2024.
Average growth rate-26.82%
More ▼

Revenue history & estimates in USD

NeoGenomics, Inc. had 3rd quarter 2024 revenues of 167.82m. This bettered the 167.01m consensus of the 13 analysts covering the company. This was 22.30% above the prior year's 3rd quarter results.
Average growth rate+2.53%
NeoGenomics, Inc. had revenues for the full year 2023 of 591.64m. This was 16.07% above the prior year's results.
Average growth rate+9.75%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.